Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
IDNAvsARKGETF Comparison
iShares Genomics Immunology and Healthcare ETF (IDNA) and ARK Genomic Revolution ETF (ARKG) belong to the same industry segment: BioTech & Genomics. Both ETFs have the same top 3 sector exposures: and Health Care. IDNA is less expensive with a Total Expense Ratio (TER) of 0.47%, versus 0.75% for ARKG. IDNA is up 14% year-to-date (YTD) with +$5M in YTD flows. ARKG performs worse with -4.22% YTD performance, and -$14M in YTD flows. Run a side-by-side ETF comparison of IDNA and ARKG below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
IDNA vs ARKG performance and flow charts
Performance
Cumulative Flows
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | IDNA ARKG | +2.96%-3.97% | +12.62%-10.24% | +14.00%-4.22% | +39.25%+27.40% | +33.46%+1.75% | -34.44%-68.08% |
| Flows | IDNA ARKG | +$5M-$69M | +$5M-$81M | +$5M-$14M | +$293K-$206M | -$22M-$635M | -$964K-$2.75B |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | IDNA ARKG | +22.83%+39.15% | +25.56%+44.66% | +24.01%+42.31% | +28.14%+45.26% |
| Max drawdown | IDNA ARKG | -6.17%-19.50% | -18.64%-23.94% | -30.61%-51.98% | -68.19%-80.33% |
| Max drawdown duration | IDNA ARKG | 29d47d | 127d77d | 279d965d | 1634d1821d |
IDNA | ARKG | |
Last sale 3/11/2026 at 7:59 PM | $29.96 | $26.84 |
| Previous close 03/11/2026 | $29.85 | $27.67 |
| Consolidated volume 03/11/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
IDNA | ARKG | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
IDNA | ARKG | |
|---|---|---|
| Last price | $29.96 | $26.84 |
| 1D performance | +0.37% | -3.00% |
| AuM | $153.72 M | $1.11 B |
| E/R | 0.47% | 0.75% |
IDNA | ARKG | |
|---|---|---|
| Management strategy | Passive | Active |
| Provider | iShares | Ark Investment |
| Benchmark | NYSE FactSet Global Genomics and Immuno Biopharma Index | - |
| N° of holdings | 42 | 30 |
| Asset class | Equities | - |
| Trailing 12m distribution yield | Join | Join |
| Inception date | June 11, 2019 | April 2, 2019 |
| ESG | No | No |
Countries
Sectors
Diversification
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Top 15 holdings
How have the IDNA and ARKG ETFs performed in 2026?
As of March 11, 2026, IDNA is up 14% year-to-date (YTD), while ARKG has lost -4.22%. That puts IDNA better performer ahead so far this year.
Which ETF is attracting more investor money: IDNA or ARKG?
Year-to-date, the IDNA ETF saw +$5M in flows, compared to -$14M for ARKG.
Which ETF is more volatile: IDNA or ARKG?
Over the past year, IDNA had a volatility of 25.56%, while ARKG experienced 44.66%.
Which ETF is bigger: IDNA or ARKG?
As of March 11, 2026, IDNA holds $153.72 M in assets under management (AUM), while ARKG manages $1.11 B.
What sectors do the IDNA and ARKG ETFs invest in?
IDNA leans toward sectors like Health Care. Meanwhile, ARKG focuses on Health Care.
What are the top holdings of the IDNA ETF and ARKG ETF?
IDNA top holdings include MODERNA INC, BAYER AG and REVOLUTION MEDICINES INC. ARKG holds in its top three: CRISPR THERAPEUTICS, PERSONALIS INC and GUARDANT HEALTH INC.
Which ETF is more diversified: IDNA or ARKG?
IDNA holds 51 securities with 62.44% of its assets in the top 15. ARKG has 30 securities and a top 15 weight of 63.79%.
Calamos Investments Powers the Next Phase of the Autocallable Revolution
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
